• Underwriting agreement provides minimum $4.5m and up to $6.0m in funding
• Funds to support commercialization of ColoSTAT® and geneType™ diagnostic platforms
• Strengthens company's funding position as it progresses commercialization

Rhythm Biosciences Ltd (ASX: RHY), a transformative, predictive cancer diagnostics technology company, has entered into a binding option underwriting agreement with CPS Capital Group Pty Ltd to partially underwrite the exercise of listed options (ASX: RHYO) exercisable at $0.20 each and expiring on 31 March 2026. Under the agreement, the underwriter has agreed to subscribe for up to 30,000,000 shares corresponding to unexercised options, representing a maximum underwriting commitment of $6,000,000 (before costs). The underwriting provides the company with a minimum commitment of $4.5 million, which will be used to support the ongoing commercialization of the ColoSTAT® and geneType™ diagnostic testing platforms, as well as general working capital purposes. The company intends to issue the shortfall shares under its existing placement capacity or subject to shareholder approval. The underwriting agreement contains customary termination events, and the underwriter will receive a fee of up to 6% of the final underwritten amount, as well as the issuance of 3,000,000 options plus additional options on a 1 option for 3 shares underwritten basis.

The additional capital provides increased funding certainty as the company continues to execute its commercialization strategy both domestically and internationally with its product portfolio.